538 Background: Advanced HCC after failure of first line immunotherapy has limited options and is an urgent unmet need. Trans-arterial Tirapazamine embolization (TATE) is a locoregional therapy capable of inducing tumor necrosis and generating anti-tumor T cells. We investigated the efficacy and safety of TATE with Nivolumab (nivo) in salvage setting. Methods: The study was an open-label single-arm, multi-center Phase 2 study (NCT03259867). Advanced HCC patients who progressed on at least one line of dual immunotherapy, ECOG 0-2, Child-Pugh 5-7, BCLC-C, with liver tumor > 2 cm but 80 clones and new CDR3 clones with > 100 copies comprising 10-20% of the total CDR3 post-TATE. Further details will be presented at the meeting. Conclusions: TATE plus nivo is promising in the salvage setting of advanced HCC patients who failed at least one line of immunotherapy. Further investigation is warranted to confirm the efficacy of this combination. Clinical trial information: NCT03259867 . Best overall response in all evaluable patients. mRECIST n=18 (%) RECIST n=18 (%) RR 10 (55.6%) 3 (16.7%) CR 4 (22.2%) 0 (0%) PR 6 (33.3%) 3 (16.7%) SD 5 (27.8%) 11 (61.1%) DCR 15 (83.3%) 14 (77.8%) PD 3 (16.7%) 4 (22.2%)
Abi-Jaoudeh et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: